Neovacs SA (ALNEV.PA)

ALNEV.PA on Paris Stock Exchange

0.94EUR
4 Sep 2015
Change (% chg)

€-0.03 (-3.09%)
Prev Close
€0.97
Open
€0.96
Day's High
€0.96
Day's Low
€0.93
Volume
227,901
Avg. Vol
426,667
52-wk High
€4.04
52-wk Low
€0.86

ALNEV.PA

Chart for ALNEV.PA

About

Neovacs SA is a France-based company active in the biotechnology industry. It specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The Company researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The Company... (more)

Overall

Beta: 0.81
Market Cap(Mil.): €30.13
Shares Outstanding(Mil.): 32.06
Dividend: --
Yield (%): --

Financials

  ALNEV.PA Industry Sector
P/E (TTM): -- 66.08 35.95
EPS (TTM): -0.33 -- --
ROI: -121.73 0.57 14.99
ROE: -442.02 0.41 15.87
Search Stocks

BRIEF-Neovacs receives first regulatory approvals for a phase IIb trial of IFNalpha-Kinoid in Lupus

* Receives first regulatory approvals for a phase IIb trial of IFNalpha-Kinoid in Lupus

01 Sep 2015

BRIEF-Neovacs closes 7.5 mln euro capital increase

* Announces closing of 7.5 million euro ($8.30 million) capital increase with U.S. investors

02 Jul 2015

BRIEF-Neovacs successfully raises EUR 7.5 million from institutional American investors

* Successfully raises 7.5 million euros ($8.39 million) from institutional American investors

26 Jun 2015

BRIEF-Neovacs initiates clinical program in Dermatomyositis

* Extends its IFNalpha-Kinoid program to include dermatomyositis beyond lupus to include adult and pediatric DM

16 Jun 2015

BRIEF-Neovacs receives 1.8 million euros in research tax credit

* Says it has received 1.8 million euros ($2.02 million) in research tax credit for research and development expenses incurred in 2014

13 May 2015

BRIEF-Neovacs announces establishment of wholly-owned US subsidiary

* Neovacs strengthens North American presence with formation of U.S. Subsidiary

23 Mar 2015

BRIEF-Neovacs appoints two new officers to scientific leadership team

* Says Geraldine Grouard-Vogel, Pharm.D., Ph.D., appointed Chief Scientific Officer Source text for Eikon: Further company coverage: (Gdynia Newsroom)

11 Mar 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks